Sector Update: Health Care Stocks Slipping in Afternoon Trade; ICU Medical Tops Q2 Expectations, Raises FY14 EPS Outlook

Top Healthcare Stocks

JNJ -0.73%

PFE -0.41%

ABT -1.29%

MRK +0.48%

AMGN -1.14%

Healthcare stocks were moderately lower today with the NYSE Healthcare Sector Index dropping about 0.2% and shares of healthcare companies in the S&P 500 falling about 0.3% as a group.

In company news, ICU Medical ( ICUI ) was hanging on a portion of its morning gains that followed the medical device company reported Q2 net income and revenue that topped analyst expectations and also raised its forecast for full-year earnings.

ICUI shares were up about 7.3% in recent trade at $62.13 each, well off their session high of $63.89 a share. Over the past 12 months, the stock has traded within a range of $54.00 to $74.93 a share, slipping about 13.5% during that span.

The company posted Q2 GAAP net income of $5.9 million, or $0.38 per share, down from a $7.4 million GAAP profit last year but beating the Capital IQ consensus by $0.04 per share. Revenue inched just 0.1% above year-ago levels to $78.6 million but still topped analyst estimates by around $4.53 million.

International sales rose 12% year over year, helping offset a 4% decline in domestic revenue that was largely due to a a drop in sales of its infusion therapy devices.

Looking forward, the company raised the bottom end of its forecast for per-share earnings by $0.15 while boosting the top end of its EPS guidance by $0.05 over its prior outlook. It now sees earnings in a range of $1.30 to $1.50 per share, in-line with the Street view looking for a $1.38 per share gain this year.

In other sector news,

(+) ICPT, (+26.1%) Said 46% of patients with non-alcoholic steatohepatitis treated with its obeticholic acid drug candidate did not suffer further liver scarring compared with only 21% in placebo group. Now planning late-stage trial during first half of 2015.

(-) INSM, (-4.0%) Begins $80 mln underwritten offering of its common stock. At Monday's closing price of $11.81 a share, the company would issue around 6.77 mln shares. Proceeds will fund clinical development of Arikayce treatment for cystic fibrosis.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Founded in 1999, MT Newswires (formerly known as Midnight Trader) is a leading provider of original source, multi-asset class, real-time, global financial news and information to most of the largest banks, brokerage firms and professional market data, trading & research applications in North America.

    Learn More